Hod Hasharon, Israel & Shanghai – September 07, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.
Pivotal China trial clears statistical bar with wide margin over placebo
The registration study, conducted with Fosun Pharma affiliate JuveStar, enrolled 360 patients on active treatment and 120 on placebo, evaluating efficacy 84 days after one treatment cycle. Results showed a decisive statistical advantage across all measured endpoints, according to the companies.
Companies target China NDA submission by end of 2026
Raziel and Fosun plan to file a New Drug Application with China's regulator by year-end 2026, positioning RZL-012 as a potential first-in-class fat-reduction treatment for the country's medical aesthetics market. The compound is administered subcutaneously by trained physicians in one to two injection sessions and works by destroying targeted fat cells so they can no longer store fat.
Fosun expands bet to body contouring as next indication
Beyond submental fat, Fosun is preparing a follow-on trial evaluating RZL-012 for body contouring, extending the compound's reach into the broader focal fat reduction category. The companies frame this segment as large and underpenetrated, and complementary to the current surge in systemic weight-loss therapies reshaping the aesthetics and metabolic health markets.
Alon Bloomenfeld, Founder and CEO of Raziel Therapeutics, said the data demonstrate the compound's superiority in focal fat reduction and its potential to become a standard treatment across aesthetic indications. Phillip Cui, Co-CEO of Fosun Health Capital, said the results reinforce confidence in RZL-012's ability to address unmet need in medical aesthetics.